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Abstract
Johne’s disease is a chronic diarrhea affecting all ruminants. Mycobacterium avium subsp. 
paratuberculosis (MAP), a slowly growing mycobacteria, is the etiologic agent. There is also 
a concern that MAP might be a causative agent of some cases of inflammatory bowel dis-
ease in humans, especially Crohn’s disease. Food products including pasteurized bovine 
milk have been suggested as potential sources of human infection. This review addresses 
microbial factors that may contribute to its pathogenicity. In addition, the experimental ev-
idence defining MAP as the cause of Johne’s disease and the issues and controversies sur-
rounding its potential pathogenic role in humans are discussed.
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Introduction
Mycobacteria (taxonomically referred to as the genus Mycobacterium) include a 
group of high GC gram-positive microorganisms comprising more than 100 spe-
cies. Although most of these species are saprophytic, important human and ani-
mal pathogens have been identified. Pathogenic members are usually character-
ized by their slow growth in culture, with generation times of 12 to 24 h, whereas 
nonpathogenic members grow considerably faster. Taxonomical classifications 
place the genus Mycobacterium as a relative of the genera Corynebacterium, Nocar-
dia, Rhodococcus, and Streptomyces. Mycobacteria are characterized by their acid-
fastness and lipid-rich cell wall. The main pathogenic species include Mycobac-
terium avium, M. bovis, M. leprae, and M. tuberculosis. Mycobacterium avium subsp. 
paratuberculosis (MAP) is the etiologic agent of Johne’s diseases in ruminants and 
is also associated with Crohn’s disease in humans (72).
The Microorganism
M. avium subsp. avium (MAV) and M. intracellulare have long since been recog-
nized as opportunistic human pathogens for patients with chronic respiratory in-
fections, such as obstructive lung disease. More recently, these microorganisms 
have been associated as major opportunistic pathogens of immunosuppressed in-
dividuals, especially AIDS patients (88). Because of this close clinical relationship 
in human medicine, both species are often called the M. avium complex (MAC). 
Technically, this term should apply to all the subspecies of M. avium, including 
MAP and M. avium subsp. silvaticum. However, this is rarely recognized in hu-
man infectious disease. Only recently have a limited number of MAP infections in 
AIDS patients been reported (134), and no cases have implicated M. avium subsp. 
silvaticum. A key report regarding the close relationship among the subspecies 
of M. avium was the study by Thorel et al. (160). Several isolates were subjected 
to a battery of genotypic and phenotypic tests and correlated with prior studies 
on DNA-DNA hybridization tests. This analysis led to the subdivision of the M. 
avium group into the three subspecies mentioned above. MAP is the subspecies 
with the slowest growth rate, with a generation time of over 20 h that varies with 
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the number of microorganisms present in the inoculum (99). Moreover, MAP is 
the only subspecies that depends on the siderophore mycobactin for growth, es-
pecially when grown as a primary culture directly from animal tissues. However, 
upon replication in culture, mycobactin is not an absolute requirement if the ap-
propriate medium and starting pH are used (100).
Animal and Human Isolates 
The next level of variability observed among MAP isolates from animal and hu-
man origins strikingly resembles the situation with MAV (88). Animal isolates 
have been linked to Johne’s disease in ruminants and wildlife, and isolation 
from human specimens has been related to a potential etiology of Crohn’s dis-
ease (CD). Restriction fragment length polymorphism (RFLP) analysis identifies 
three patterns, including mostly ovine (pattern A), bovine (pattern B), or caprine 
(pattern C) isolates (130). The sole human isolate analyzed, strain Linda, followed 
pattern B. Further analysis by RFLP and PCR-restriction endonuclease analysis 
of IS900 and IS1311 polymorphisms established the widely used nomenclature of 
C and S strains (172). C strains included most bovine isolates, isolates from wild-
life, and two human isolates. Another more recent study by pulsed field gel elec-
trophoresis combined with analysis of polymorphisms distinguished pigmented 
(type I) sheep isolates from nonpigmented (type II) isolates (153). Further stud-
ies by comparative DNA sequencing and representational difference analysis (a 
type of PCR-based subtractive DNA methodology) demonstrated an 11-bp inser-
tion in a novel region of MAP genomic DNA (50). Comparative genomic tests 
failed to identify unique type-specific loci but demonstrated a greater number 
of deletions and rearrangements in type II strains when compared with MAV. 
In general, these studies indicated that MAP strains appear to cluster into two 
groups: slowly growing ovine strains and broad-host-range strains that include 
bovine, wildlife, and human isolates. As previously indicated by Stevenson et al. 
(153), there is no absolute correlation between strain type and host, with some 
ovine isolates clustering with C strains and a few bovine isolates clustering with 
S strains. Moreover, S strains can infect and produce Johne’s disease in cattle. In 
another recent study, Motiwala et al. (108) used multiplex PCR of IS900 integra-
tion loci (MPIL) and amplified fragment length polymorphism (AFLP) analyses 
to fingerprint MAP isolates recovered from animals (n = 203) and patients with 
CD (n = 7) from diverse geographic localities. Bovine isolates clustered in groups 
of high genetic similarity, while ovine and human isolates displayed a higher de-
gree of variability. Moreover, the two molecular fingerprinting methods were in-
dependent, and strains that clustered in one group by MPIL could be subdivided 
by AFLP. The salient feature of the AFLP analysis, in contrast to other previous 
studies, was the higher degree of heterogeneity displayed by the human strains. 
Expansion of this and similar types of studies to a greater number of human iso-
lates is of utmost importance to determine the likelihood of interspecies transmis-
sion between cattle and humans and the potential sources of MAP infection in 
humans (Figure 1). For example, octamer-based genome scanning identified two 
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lineages of Escherichia coli O157:H7 that are disseminated within the U.S. cattle 
population (92). This analysis indicated that some patterns recovered from both 
cattle and humans were not randomly distributed among the lineages. This sug-
gests that isolates recovered from cattle alone (bovine isolates) were not as viru-
lent for humans. In contrast, the analysis of MAP strains by AFLP, though lim-
ited in the number of human isolates, does not seem to match this trend (108). 
If bovine MAP isolates are not readily transmitted to humans, the role of raw or 
adulterated milk as a source of MAP infections in CD patients would be diffi-
cult to maintain. See Bannantine et al. (6a) for a thorough review on the develop-
ment of molecular methods to address concerns that MAP might be a foodborne 
pathogen.
Figure 1. Potential sources of MAP infection in humans. Humans can become infected 
with MAP isolates found in adulterated milk or contaminated water supplies. The molec-
ular comparison of strains by octamer-based genome scanning, multiplex PCR of integra-
tion loci, and AFLP can be used to determine the likelihood of this MAP transmission from 
cattle and/or the environment/wildlife to humans.
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Genomics 
The MAP genome has recently been sequenced at the University of Minnesota, 
St. Paul, in collaboration with the National Animal Disease Center (NADC; 
Ames, Iowa). The sequencing strain (MAP K-10) was selected on the basis of 
our previous studies (64). This strain was provided by D. Whipple (64) as a 
typical bovine isolate from a cow with Johne’s disease that had been subjected 
to a low number of passages in vitro. This would prevent loss of the virulence 
properties of the original isolate. In contrast, the American type culture collec-
tion (ATCC) type strain 19,698 has been passed in vitro more frequently. More-
over, our experiments demonstrated that strain K-10 yielded the highest effi-
ciency of transformation with plasmid DNA and was readily infected by phage. 
Strain K-10 is a typical bovine type II strain (108). A similar situation regarding 
selection of transformable and virulent isolates led us to the selection of MAC 
104 as the sequencing strain for MAV, whose genome sequence has now been 
completed at The Institute of Genomic Research (Rockville, Maryland). These 
properties of strain K-10 were of importance in developing a transposon mu-
tagenesis system (74), as well as recombinant MAP strains expressing reporter 
genes such as those encoding the firefly luciferase (174) and the green fluo-
rescent protein (75). These tools will be useful in postgenomic studies to cre-
ate mutants in defined genes to assess their contributions to MAP virulence, 
thus fulfilling the molecular version of Koch’s postulates. Moreover, compara-
tive genomics and mutant analyses of both MAP and MAV would be essential 
for a thorough understanding of how two closely related microorganisms may 
cause different disease processes. The current information on the complete ge-
nomes of MAV and MAP indicates sizes of 5.48 and 4.83 Mb, respectively. The 
MAP genome sequence was released January 2004; see http://www.ncbi.nlm.
nih.gov/entrez/viewer.fcgi?db=nucleotide&val=41400296, accession number 
AE016958. However, correction of potential sequencing errors and final anno-
tation may result in size corrections. Nonetheless, it is evident that MAP and 
MAV are highly homologous. For example, comparison of a 35-kb region en-
compassing the origins of replication of MAP and MAV showed a homology 
of greater than 97% (10). Moreover, this homology seems characteristic of the 
whole genomes as indicated by the above-cited release data. This would pre-
dict the existence of no more than 75 subspecies-specific genes, of which 21 
have been located to specific sequences (6).
Both MAP and MAV genomes possess numerous insertion elements either 
unique to the subspecies or shared by several members of the species or the ge-
nus Mycobacterium (72). For example, the MAP genome has revealed the presence 
of 17 IS900, 7 IS1311, and 3 IS1245 insertion elements. The IS900 element seems 
unique to MAP and has been widely used as a diagnostic tool to detect MAP in 
clinical samples from both animals and humans. Adequate selection of primers 
for nested PCR of IS900 is essential for specific amplification of this element (22, 
23). IS900-like elements with highly homologous but not identical sequences in 
other mycobacteria have been observed (44, 60). The presence of IS900 in MAV 
isolates from AIDS patients has also been described (115); however, these data 
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do not include sequencing information. Thus, under further scrutiny, these ele-
ments may be closely related, but not identical to IS900. For example, IS1626, a se-
quence detected in MAV, shares approximately 82% homology with IS900 (72). 
Other elements present in MAP are shared, as IS1311 is also present in M. intra-
cellulare and IS1245 is present in MAV isolates. The GS element (or IS1612) has 
been found in MAP, MAV, and the silvaticum subspecies. This 7-kb insertion se-
quence is particularly interesting because it contains genes with low GC content 
that may be associated with the biosynthesis, modification, and transfer of a fu-
cose moiety to cell wall glycopeptidolipids (144). In summary, the canonical IS900 
element seems to be a defining characteristic of the MAP subspecies, though sim-
ilar elements may be present in other mycobacteria. All these insertion elements 
may contribute to defining the pattern of gene expression in the different subspe-
cies. For example, one study found that seven IS900 insertion loci were conserved 
among all MAP strains tested and that five insertions resulted in gene inactiva-
tion (22). The genomic differences between MAP and MAV may be compounded 
by the effects of insertion elements on up- or downregulation of gene expression, 
further determining the compositions of the transcriptomes and proteomes of 
both types of microorganisms.
Antigens and Virulence Determinants 
A major antigen of mycobacterial species including MAP is lipoarabinomannan 
(LAM), which has been used in many serological tests for diagnosis of Johne’s dis-
ease (155). Other lipids and glycolipids of MAP have not been fully characterized, 
but they are expected to be similar to those from other mycobacterial species. For 
example, the same major polar glycopeptidolipid was found in the ATCC proto-
type strain 19,698 as well as in strain 18, now reclassified as MAV (26). Nonethe-
less, subtle differences in the glycolipids have been exploited to classify related 
strains of MAP and MAV (122). Serovar-specific glycopeptidolipids are not ex-
pressed by MAP or M. avium subsp. silvaticum, though the synthetic machinery 
seems to be present within the GS element (52).
Several immunoreactive proteins share homology with other mycobacterial 
antigens. These include the GroES and GroEL proteins, which are highly anti-
genic, and conserved heat shock proteins (40, 55). A major antigen that domi-
nates the humoral response against MAP is the 34-kDa cell wall antigenic protein 
(48). This antigen has homologs in other mycobacteria and shares two identical B-
cell epitopes with the MAV homolog (127). A seroreactive antigen of 34 kDa with 
a putative serine protease activity that is different from the 34-kDa antigen de-
scribed above has also been described (25). Another conserved highly immuno-
genic antigen with homologs in many bacteria is bacterioferritin, also known as 
antigen D, with a molecular mass of 400 kDa in the oligomeric form and a subunit 
molecular mass of approximately 17 kDa (20). The alkyl hydroperoxide reductase 
proteins (AhpC and AhpD), likely involved in the detoxification of reactive nitro-
gen intermediates, are also abundant immunogenic proteins of MAP in sterling 
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contrast to their low abundance in MAV when both microorganisms are grown 
under various laboratory conditions (124). Other immunogenic proteins shared 
by mycobacteria and secreted by MAP include a 32-kDa antigen (56), a 16.7-kDa 
antigen, and a manganese-dependent superoxide dismutase (SodA), and pro-
teins of the antigen 85 complex (49, 101, 110). Antigens 16.7, 85B, and SodA from 
MAP elicit T helper 1 (Th1)-type immune responses associated with protective 
immunity in mice (109–111). Protein antigens of 34.5 and 44.3 kDa have also been 
identified in culture filtrates of MAP by the use of monoclonal antibodies against 
MAP antigens, though no sequence data are available on these antigens (112). 
This study also observed the presence of glycoconjugates, which were the earliest 
antigens detected in culture filtrates.
Two antigenic proteins of importance in the context of MAP as a potential eti-
ology of CD are the p35 and p36 antigens. Antigen p35 was identified by screen-
ing a MAP recombinant library in E. coli as displaying strong reactivity against 
sera from all clinically and a significant proportion of subclinically infected ani-
mals tested (57). No public sequence information is available on this antigen, but 
the corresponding gene was shown by hybridization to be homologous to DNA 
sequences from MAV strains and isolates from wood pigeon that likely repre-
sented M. avium subsp. silvaticum. Thus, p35 seems to be a shared antigen among 
all subspecies of M. avium. Antigen p36 was reported to be an indicator of MAP 
infection in relation to the seroreactivity observed in human cases of sarcoidosis 
and CD (57–59). With the sequence information provided for this antigen, we 
searched GenBank for homologous sequences. We found a significantly homol-
ogous sequence in the genomes of MAP K-10 (about 98%) and MAC 104 (about 
97%). Thus, p36 also seems to be a shared antigen among the M. avium species. 
The amounts of p35 and p36 antigens in MAP strains have not been determined, 
and thus we do not know whether MAP strains produce larger amounts of these 
antigens than other subspecies of M. avium do.
A MAP-specific antigen is the HspX protein, a 16-kDa putative heat-shock-
like protein possessing an arginyl-glycyl-aspartic acid (RGD) peptide motif im-
plicated in mediating cell attachment and stimulating phagocytosis (53). In addi-
tion, this protein was expressed by intracellular MAP within bovine macrophages 
(9). As long as IS900 appears to be MAP-specific, IS900-encoded proteins are also 
unique to the subspecies. In this context, the more abundant protein produced by 
this element seems to be the Hed (host-expression-dependent) protein (51). How-
ever, it is unclear whether this protein is produced in large amounts to elicit an 
immune response. Another candidate for a MAP-specific protein is a 42-kDa im-
munoreactive antigen identified by comparative two-dimensional gel analysis of 
methionine-labeled cellular proteins from MAP and MAV (170). However, no se-
quence data are available on this protein. Use of comparative genomics has led 
to the discovery of 21 sequences specific to MAP ranging in size from 7 to 91 kDa 
(7). Five of these proteins were immunogenic in mice and rabbits, and they all re-
acted with sera from cattle with clinical disease. This approach promises for the 
first time to find antigens specific to MAP that could be used in serological tests 
for MAP detection in animal and human hosts.
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Few virulence determinants have been described. Attachment and internal-
ization of MAP to the intestinal mucosa appear to be mediated by a fibronectin 
binding protein. A protein of approximately 36 kDa (FAP-P) with about 90% ho-
mology to the MAV homolog was identified in MAP strains (139). This protein 
seems to be made as a precursor of 54 kDa and is located in the inner part of the 
cell envelope rather than directly on the surface. A recombinant strain carrying 
an antisense construct of FAP-P demonstrated reduced expression and attach-
ment to fibronectin (141). In addition, a 35-kDa membrane protein that reacts 
with antisera from cattle with Johne’s disease also plays a role in the invasion of 
bovine epithelial cells and is upregulated by hypoxic conditions that mimic the 
intestinal environment (8).
 
Johne’s Disease
The Disease in Ruminants 
MAP is the etiological agent of a severe gastroenteritis in ruminants known as 
Johne’s disease, a chronic enteritis with worldwide distribution and a significant 
impact on the world economy (156). In the United States, losses to the cattle in-
dustry have been estimated at $1.5 billion per year (147). Lower estimates have 
been given, but since it is difficult to assess losses in productivity and profit at an 
individual herd level, the impact of this disease may be underestimated nation-
wide (89, 128). A regression model estimates these losses to be from $40 to $227 
per cow inventoried per year (114).
The physiology and pathogenesis of MAP have been reviewed recently (72). 
Neonates and juvenile animals are the most susceptible to infections (38). Dis-
ease progression is classified in four stages: silent infection, subclinical, clini-
cal, and advanced clinical disease (171). Animals are most likely infected via 
the fecal-oral route. MAP colonizes the mucosa-associated lymphoid tissues of 
the upper gastrointestinal tract, which are endocytosed by the M-cells of the il-
eal Peyer’s patches. Bacilli are subsequently phagocytosed by subepithelial and 
intraepithelial macrophages (66, 103, 107). The antigen FAP-P may play a role 
in the binding to fibronectin that would facilitate endocytosis mediated by sur-
face integrins of the apical surface of M-cells (139). Once internalized, intracel-
lular bacilli remain and multiply in the phagosomal compartment (90). The en-
suing host cellular immune response leads to granuloma formation and the 
involvement of adjacent lymph nodes (38, 103). T-cell activation, gamma inter-
feron (IFN-γ) production, and macrophage activation take place, and this pro-
cess leads to the clinical manifestations characterized by a corrugated intestinal 
epithelium. The final consequence is the appearance of the typical malnutrition 
syndrome associated with Johne’s disease that culminates in the death of the 
animal.
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The Koch’s Postulates: Application to Johne’s Disease 
Koch’s postulates represented a landmark development for establishing the etiol-
ogy of infectious diseases. Koch applied his postulates to establish unequivocally 
that M. tuberculosis is the etiologic agent of human tuberculosis (95). Though skin 
tests have revealed that almost one third of the world’s population is infected 
(154a), only a significant but minor proportion of infected individuals develop ac-
tive disease. In the acute phase, acid-fast bacilli are evident in diseased individu-
als and the microorganisms can be readily isolated in pure culture. Moreover, iso-
lated bacilli are quite lethal to a variety of animals and can be readily reisolated 
from infected tissues of experimentally infected hosts. However, Koch’s postu-
lates may not be applied without reservations to any host-pathogen interaction. 
The case of M. leprae, the causative agent of leprosy, clearly illustrates this issue. 
This microorganism has not yet been cultured in vitro, but causation has been es-
tablished by a combination of immunological and chemotherapeutic approaches.
In the case of Johne’s disease in ruminants, the application of Koch’s postulates 
and the establishment of MAP as the causative agent were facilitated by a seren-
dipitous finding. An extract of Mycobacterium phlei allowed in vitro growth of the 
microorganisms present in animal tissues by providing mycobactin, a necessary 
nutrient for MAP in the iron-deficient conditions used for those cultures (163). Fig-
ure 2 summarizes the historical developments associated with the fulfillment of the 
Koch’s postulates for MAP and Johne’s disease. A more detailed description of the 
history of the disease is presented elsewhere (31), but the following narrative fol-
lows the history in connection with the Koch’s postulates. Our story starts in a Ger-
man farm with a cow that failed to gain weight until the animal died. In 1895, Johne 
and Frothingham analyzed the intestines and identified acid-fast bacilli, establish-
ing that bacilli could be isolated from infected animals. Koch’s postulates require 
growing the agent in pure culture and this was accomplished by F. Twort, who iso-
lated the bacillus in 1910. The final test of the postulates was to reintroduce the ba-
cilli in susceptible animals and show that laboratory animals developed a compa-
rable disease. Twort accomplished this aspect in 1914 (162). However, the animal 
model plays a critical role at this final stage and it is often difficult to draw conclu-
sions that will apply to the homologous host. The postulates were fulfilled in 1933, 
when Hagan & Zeissig reported in their six-year study that a herd had been experi-
mentally infected with MAP (70). Since then, the establishment of the Koch’s postu-
lates for Johne’s disease has led control and eradication efforts.
Significant research efforts are directed toward the identification of genes and 
their products that may be involved in the pathogenesis of Johne’s disease. In this 
context, our goal is to fulfill a molecular version of the Koch’s postulates (62). Fig-
ure 3 depicts an in vitro version using bovine macrophages. Individual transposon 
mutants of MAP are tested for survival in bovine macrophages, and mutant strains 
with impaired survival are identified. Molecular procedures are then used to iden-
tify the mutated genes and the wild-type homologs are reintroduced back into the 
mutant strains with the expectation that macrophage survival is restored. For in 
vivo experiments, strains are then tested in small-animal models and ruminants.
Figure 2. Historical milestones associated with Koch’s postulates. In ruminants, the etio-
logic agent of Johne’s disease was established as MAP by applying Koch’s postulates (left). 
Historical events (right) indicate how the various postulates were fulfilled.
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Figure 3. A molecular version of Koch’s postulates. Transposon mutants of MAP are tested 
in vitro for survival in bovine macrophages. Molecular procedures identify genes and their 
products involved in the pathogenesis of Johne’s disease.
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Animal Reservoirs and Diagnostics from Clinical Samples 
MAP is a microorganism with a wide host range, and infections have been re-
ported not only in ruminants but also across many species including badger, bi-
son, camelids, deer, elk, fox, primates, rabbits, and swine. Particularly interest-
ing are two cases in primates that resemble Johne’s disease in ruminants. These 
findings seem to indicate that nonruminant wildlife may be a natural reservoir 
for MAP (17a). Three interesting studies performed in Scotland underscore the 
role of rabbits in the transmission of paratuberculosis (12, 13, 69). These studies 
indicated a correlation between the number of infected rabbits and infected cat-
tle. This opens the possibility that cattle may consume pastures with fecal pel-
lets from infected rabbits and thus acquire MAP. Moreover, MAP strains isolated 
from rabbits in these farms are closely related to cattle strains and produce dis-
ease in experimentally infected cattle. Badgers and foxes consume rabbits as food, 
and thus, these carnivores are likely to be infected with MAP by this food chain. 
The infection cycle may be completed by transmission of environmental MAP 
from water supplies, whose pathogenicity may be enhanced by intracellular mul-
tiplication within protozoans as shown for MAV (37). It can then be speculated 
that environmental MAP carried in protozoan hosts are the source of rabbit infec-
tions, with these animals transmitting MAP to cattle and even carnivores through 
the food chain.
Methods to diagnose MAP from clinical samples have been reviewed else-
where (42, 72). In general, methods can be divided into those that detect the mi-
croorganism or its DNA, and those that look for a specific host reaction against 
MAP antigens. All methods may be then compared with the “gold standard” 
of culturing the microorganism from fecal samples. The most widely used PCR 
method is based on the detection of the IS900 element. The immune-response-
based methods include a skin test, an INF-γ-ELISA test for cellular immunity, 
and the widely used ELISA-LAM or ELISA-protoplasmic antigen humoral 
tests. With some caveats, these methods have high specificity but lack sensitiv-
ity to detect subclinically infected animals. INF-γ-ELISA becomes positive ear-
lier during disease progression, whereas the humoral tests become positive at 
a later stage. Likewise, fecal culture is negative for afflicted animals that shed 
a low number of bacilli, and ovine strains need specially modified medium for 
culture (173). The use of two to three different tests or serial testing is recom-
mended, but none of the diagnostic tests are capable of detecting all subclini-
cally infected animals.
Pathological and Immunopathological Findings in Diseased Animals 
The pathology of paratuberculosis is characterized by chronic enteritis, chronic 
lymphangitis, or mesenteric lymphadenopathy (21). Granulomatous lesions may 
be patchy, mild, or severe, and are usually localized in the distal intestine, the il-
eocecal lymph nodes, or the adjacent area of the colon beyond the ileocecal valve. 
Infiltrates of lymphocytes, macrophages, and plasma cells are observed and are 
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either diffused or focalized according to the severity of the infection becoming 
transmural (throughout the entire thickness of the wall). Extraintestinal cases in 
liver or kidneys also occur (79). However, affection of the villi of the mucosal ep-
ithelium of the ileum is the major component of the pathogenesis resulting in the 
malabsorption syndrome (see below for a comparison with human inflammatory 
bowel disease).
The immunopathology of paratuberculosis stems from MAP being a faculta-
tive intracellular pathogen. In this context, the ability of MAP to survive within 
macrophages plays a critical role in disease development (72). It appears that in-
tracellular multiplication and killing occur simultaneously, reflecting an initial 
Th1 cellular immune response of the host that switches to Th2 in animals with 
clinical disease (177). This T-cell response may be pivotal in activating intestinal 
macrophages, as mice deficient in T-cells have a marked reduction in the num-
ber of activated macrophages (159). Nutritional and hormonal factors influence 
host susceptibility. Reduced dietary calcium protects beige mice from MAP infec-
tions (149), but a corresponding increase in endogenous vitamin D reverses the 
beneficial effects of low calcium (148, 149). Transient exposure of monocytes to 
growth hormone or prolactin enhances intracellular multiplication in primary bo-
vine monocytes (63).
Mycobacteria are relatively resistant to the bactericidal mechanisms of pro-
fessional phagocytes. Catalase and peroxidase are involved in resistance to re-
active oxygen intermediates (28, 104), and AhpC, a major antigen of MAP (124), 
may be important to protect against both oxygen and nitrogen reactive inter-
mediates (29, 104). Likewise, the secreted antigen 85B elicits high production of 
IFN-γ, nitric oxide (NO), and interleukin (IL)-10 in spleen cells of immunized 
mice (109). In contrast, stimulation with SodA increases production of IFN-γ, 
but lowers NO and IL-10 production (111). Furthermore, the host T-cell popu-
lation may influence the production of reactive intermediates by professional 
phagocytes, as athymic nude mice produce significantly less inducible NO syn-
thase (159). Treatment of MAP-infected bovine monocytes with IFN-γ induces 
release of NO, but the levels seem insufficient to kill MAP in vitro (176). Simi-
larly, growth of MAP in the J774 murine macrophage cell line can be influenced 
by prior exposure of the macrophages to different levels of tumor necrosis fac-
tor alpha (TNF-α) (146). Moreover, activation of J774 macrophages by IFN-γ or 
lipopolysaccharide (LPS) leads to increased colocalization of MAP with acidic 
late endosomal compartments, suggesting a more efficient killing of intracellu-
lar bacilli (81).
The exact mechanism of how MAP influences normal antigen processing in 
macrophages is unknown. In murine cultured macrophages from the J774 cell 
line, MAP seems to undergo a growth phase during the first 24 h postinfection, 
followed by a slow decline in viability for the next six days (4). On the basis of 
the selective exclusion of specific subcellular markers in J774 macrophages, other 
studies have shown that both MAP and MAV can persist within phagosomal 
compartments for up to 15 days (98). MAP, MAV, and M. tuberculosis all appear 
to inhibit phagolysosomal fusion (39, 121) and acidification (98, 121). However, 
340   Ch aC o n, Be r mu d ez, & Bar l etta i n Ann u A l Re vi e w of Mi cR ob i ol og y  58 (2004) 
because the interaction between the ruminant immune system and MAP may not 
follow similar interactions between human and murine host cells and other my-
cobacteria, the use of these murine or human models and cell lines may not ac-
curately reflect the infection in the ruminant host. For example, after infection of 
J774 macrophages with both MAP and MAV, numbers of intracellular MAP de-
creased while MAV increased over a four-day period (98). Recent studies with 
a bovine macrophage cell line demonstrated that patterns of gene expression 
in macrophages are different upon phagocytosis of latex beads, E. coli, or MAP 
(161). Likewise, primary bovine monocytes react differently to MAV or MAP in-
fections, since only the latter seems to induce a suppression of macrophage acti-
vation mediated by oversecretion of IL-10 (169). In studies with primary bovine 
macrophages, live not dead MAP stimulates apoptosis (4). Moreover, stimula-
tion of monocytes from MAP-infected cattle leads to downregulation of gene ex-
pression in clinically infected animals and upregulation in subclinically infected 
cattle (46). In addition, infection with MAP appears to reprogram the pattern of 
gene expression of bovine macrophages (45). A recent study showed that whole 
blood from infected cattle in the subclinical stage had a lower expression of TNF-
α, RANTES, and monocyte chemoattractant protein 1 compared with that from 
uninfected cattle (24). Overexpression of IL-10 may mediate this effect. The out-
come of this state of immunosuppression would be to weaken protective immu-
nity, reduce granuloma formation, and perpetuate the infection.
Genetic Basis of Resistance and Susceptibility 
Host genetic factors influence the degree of susceptibility to infectious diseases. 
Use of recombinant mouse strains led to the identification of a dominant gene 
on chromosome 1 encoding the integral membrane protein NRAMP1 (natural re-
sistance associated macrophage protein 1). This protein is expressed in macro-
phages and is involved in transport of divalent cations (68). In addition, alleles 
of NRAMP1 in the mouse were associated with natural resistance to brucellosis, 
leishmaniasis, and tuberculosis, diseases caused by intracellular pathogens sub-
verting macrophage defenses. These findings were also applicable to other intra-
cellular pathogens such as MAP. Homologs of the NRAMP1 gene are found in 
cattle and humans. Polymorphisms in NRAMP1 were analyzed in cattle naturally 
susceptible or resistant to tuberculosis, but no association between these two pa-
rameters was found (11). Thus, at least in cattle, it seems that another locus or 
loci may control the resistance/susceptible phenotype. In humans, some correla-
tion has been found between NRAMP polymorphisms and tuberculosis suscep-
tibility (14, 93), but this association is stronger in mice. The ongoing project on 
the sequencing of the bovine genome at the Baylor College of Medicine (Hous-
ton, Texas) opens exciting possibilities to the discovery of disease-resistant genes 
in cattle: http://hgsc.bcm.tmc.edu/projects/bovine. Comparative genomic ap-
proaches may then be applied to characterize disease-resistant genes across the 
various dairy and beef breeds and determine whether any would have greater 
natural resistance to MAP infection.
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Inflammatory Bowel Disease
Crohn’s Disease and Ulcerative Colitis 
Inflammatory bowel disease (IBD) is a general term that describes a group of 
chronic gastrointestinal inflammatory disorders of unknown or still unproven 
etiology. The disease was originally described by Crohn, Ginzburg, and Oppen-
heimer in 1932 (47). IBD affects millions of people worldwide; and in the United 
States alone, the Crohn’s and Colitis Foundation of America has estimated that 
there are about one million individuals affected. IBD may affect male and female 
adults and children equally, and it has a peak age at onset between 15 and 25 
years of age. A lesser peak age at onset exists between 55 and 65 years of age. 
Moreover, IBD is on the rise in northern Europe and North America (151). Dis-
ease prevalence is higher in urban rather than rural areas and in some popula-
tions, such as in Ashkenazi Jews (65a). IBD can be divided in two major groups, 
ulcerative colitis (UC) and Crohn’s disease (CD). UC is characterized by diffuse 
mucosal inflammation that involves the rectum and may extend in continuity, 
without areas of intact mucosa, to all or part of the colon. In 10 to 20% of pa-
tients with total colitis, the inflammatory process may extend into the terminal il-
eum. CD is characterized by transmural inflammation that involves any segment 
of the gastrointestinal tract from the mouth to the anus, although it often spares 
the rectum (Figure 4). It may also involve the liver and the pancreas. When the 
disease affects the small intestine, it is also known as regional enteritis. In con-
trast with UC, CD is segmental, with spared areas of normal mucosa surrounded 
by diseased tissue, a characteristic that gives the disease a macroscopic patchy or 
“cobblestone” appearance. Extraintestinal symptoms are also associated with IBD 
and are more common in patients with perianal CD. They include, among others, 
dermatologic, rheumatologic, ocular, hepatobiliary, and urologic manifestations 
(65a, 104a, 178).
In summary, diarrhea is one of the major symptoms in the clinical presenta-
tions of IBD. In UC, it is usually accompanied by rectal bleeding, mucus, fecal 
urgency, tenesmus, and left lower quadrant cramps relieved by defecation. Mild 
or moderate disease may be accompanied by low-grade fever, anemia, and hy-
poalbuminemia. Severe disease is characterized by more than six bloody bowel 
movements per day, leading to anemia, hypovolemia, tachycardia, and hypoal-
buminemia. Abdominal pain and tenderness are usually present. Extracolonic 
manifestations such as erythema nodosum, pyoderma gangrenosum, episcler-
itis, thromboembolia, and oligoarticular arthritis are associated with active dis-
ease. In contrast, uveitis, ankylosing spondylitis, and sclerosing cholangitis may 
be present independent of colitis activity. In CD, chronic diarrhea is usually ac-
companied by fever, abdominal pain, anorexia, weight loss (of up to 10 to 20% of 
body weight), and a right lower quadrant mass or fullness. In some patients, the 
first signs of the disease may be acute abdomen or intestinal obstruction. Inflam-
mation in CD may result in either a fibrostenotic-obstructing pattern or a pene-
trating-fistulous pattern of disease. Diarrhea is usually nonbloody and intermit-
tent. A mass may be palpable in the right lower quadrant of the abdomen, and 
Figure 4. Anatomical regions affected by IBD. UC (green) is characterized by mucosal in-
flammation of the rectum and colon. CD (red) has transmural inflammation of any gastro-
intestinal tract segment except the rectum. The areas shaded in blue and red indicate lo-
cations where both UC and CD may be encountered. The areas shaded in blue and green 
indicate locations where UC predominates and CD is less frequent.
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it consists of inflamed bowel, adherent and indurated mesentery, and enlarged 
lymph nodes. Edema, wall thickening, and fibrosis within the mass may lead to a 
narrowed intestinal lumen. The early stages of ileocolitis are characterized by in-
termittent obstruction and postprandial pain followed, after several years, by fi-
brostenotic narrowing and strictures. Diarrhea will then be less frequent, being 
replaced by chronic bowel obstruction with some acute episodes and constipa-
tion. Inflammation of the ileocecal region may lead to wall thinning and micrope-
rforation, with fistula formation.
Malabsorption and steatorrhea are common in patients with jejunoileitis. In 
these patients, bacterial overgrowth in obstructions or fistulas, bile-acid malab-
sorption, and intestinal inflammation during active disease may cause diarrhea. 
Nutritional deficiencies and intestinal malabsorption may result in a wide vari-
ety of systemic manifestations, including vertebral fractures, pellagra, and meg-
aloblastic anemia. Patients with colitis may present low-grade fever, abdominal 
cramps, malaise, and diarrhea. Severe inflammation may result in toxic megaco-
lon. If stricture occurs, symptoms of bowel obstruction may be present. Vomiting 
may be present when fistulization occurs into the stomach or duodenum. If fistu-
lization occurs into the proximal or mid-small bowel, it may result in malabsorp-
tion. Rectovaginal fistulas may be also present. One third of patients with large 
or small bowel involvement develop perianal disease, with anal fissures, perianal 
abscesses, large hemorrhoid tags, and fistulas. Nausea, vomiting, and epigas-
tric pain suggest gastroduodenal involvement in CD. Severe disease may result 
in chronic gastric outlet obstruction. Extraintestinal manifestations of CD include 
those described for UC. Additionally, oral aphtous lesions, gallstones, and neph-
rolitiasis may occur (65a, 104a, 178).
Pathological and Immunopathological Findings in Inflammatory Bowel Disease 
Pathological and immunopathological findings in IBD are described elsewhere 
(65a, 104a). The Gastroenterology and Hepatology Resource Center at The John 
Hopkins Medical Institutions (Baltimore, Maryland) has further illustrative ex-
amples and guided easy-to-follow descriptions: http://www.hopkins-gi.org/
pages/latin/templates/. In UC, there is an inflammatory reaction primarily in-
volving the colonic mucosa. Grossly, the colon appears ulcerated, hyperemic, and 
unusually hemorrhagic. A characteristic aspect of the inflammation is that it is 
uniform and continuous, with no areas of normal mucosa present. The rectum is 
involved in 95% of the cases. The surface mucosal cells, as well as the crypt epi-
thelium and submucosa, are involved in the inflammatory reaction, with infiltra-
tion of neutrophils. This picture progresses to epithelial damage with loss of sur-
face epithelial cells resulting in multiple ulcerations. Infiltration of the crypts by 
neutrophils often results in characteristic small crypt abscesses and their even-
tual destruction. Loss of the crypt epithelium, loss of goblet cells, and submucosal 
edema may occur. Following frequent cycles of inflammation, mild submucosal 
fibrosis can develop. Unlike CD, deeper layers of the bowel beneath the submu-
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cosa are not usually involved. In severe cases of UC, the bowel wall may become 
extremely thin, leading to possible dilatation and subsequent perforation. Recur-
rent inflammation leads to characteristic features of cronicity, such as fibrosis and 
retraction. As a consequence, the colon becomes shortened and “smooth.” In pro-
longed cases of UC, the surface epithelium may show features of dysplasia. Sig-
nificant dysplasia in colonic biopsies is associated with significant risk of coexis-
tent carcinoma.
In contrast, CD is characterized by chronic inflammation extending through 
all layers of the intestinal wall and involving the mesenteric as well as regional 
lymph nodes. This basic process occurs in any place of the small or large intes-
tine. One of the most distinctive macroscopic features of CD is the sharp demar-
cation of the segmental bowel involvement, which may occur in any level of the 
intestine. Initially, CD is undefined, with the ileum appearance being usually hy-
peremic and the mesenteric lymph nodes swollen. At this stage of the disease 
the bowel wall is only edematous. Approximately 80% of patients with this pre-
sentation are infected with Yersinia enterocolitica, an organism capable of produc-
ing limited inflammatory ileitis. The most characteristic histologic features of CD 
are transmural inflammation (affecting all the layers of the serosa), noncaseating 
granulomas (resembling those of sarcoidosis), dilatation of the lymphatic chan-
nels, and lymphoid aggregates in all levels of the intestines. Granulomas are the 
most helpful microscopic feature to distinguish CD from other forms of IBD. As 
the disease progresses, the gross appearance becomes characteristic. The bowel 
wall becomes thickened and the lumen narrows. This stenosis, typical of the dis-
ease, can occur in any portion of the intestine and may be associated with varying 
degrees of obstruction. The mesentery appears greatly thickened and fatty and 
often extends over the serosal surface of the bowel. The mucosa can be normal or 
have minor manifestation of disease, in contrast to that observed in UC. The dis-
ease is usually discontinuous, with areas of normal bowel separated from each 
other by areas of severe disease. A large percentage of patients do not have dis-
ease in the rectum, in sharp contrast to those with UC.
Another important aspect of the potential role of MAP in IBD disease is the 
pathological resemblance between Johne’s disease and CD (Figure 5). Both are 
transmural diseases, though the transmural condition is rare in Johne’s disease. 
There are also important differences, most notably the absence of fibrosis, fis-
sures, fistulas, and pseudopolyps in Johne’s disease, features usually found in CD 
(17a). In contrast, UC does not display transmural alterations.
Possible Etiologies of Inflammatory Bowel Disease in Humans 
The etiology of IBD has not been defined. The current consensus hypothesis is 
that in genetically predisposed individuals (as suggested by epidemiological and 
genetic data) exogenous factors (e.g., infectious agents, normal flora) and host 
factors (e.g., intestinal epithelium, vascular supply, hormones, neuronal activity) 
act together to cause and maintain a chronic state of dysregulated mucosal im-
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mune function that may be affected by specific environmental factors (e.g., smok-
ing, chemicals). A chronic infectious agent may be responsible for the sustained 
activation of the mucosal immune system. However, such an agent has not yet 
been identified. Hence, IBD is currently considered the result of an inappropriate 
immune response with or without some autoimmunity component (65a).
THE NONINFECTIOUS ETIOLOGY HYPOTHESIS  
The theory that an immune mechanism may be involved is based on the concept 
that the extraintestinal manifestations that may accompany these disorders may 
represent autoimmune phenomena. Thus, therapeutic agents are active because of 
their effects on the immune mechanisms. Furthermore, through the study of pa-
tient and mouse models it has emerged that CD is driven by the production of IL-
12 and IFN-γ in a type of Th1 response (123). In contrast, UC is probably driven 
by the production of IL-13 (97). More recently, IL-18 polymorphism has been as-
sociated with increase risk of CD (157). In general, the transcripts to proinflamma-
tory cytokines are elevated in CD, possibly representing disease activity. In this 
case, the measure of cytokines can be used as an indication of active disease and 
as a marker for response to therapy. Patients with CD may have antibodies to co-
Figure 5. Colon histology of humans and animals with normal and inflammatory condi-
tions. (a) Normal histology of the human colon with no granulomatous lesions. (b) Pathol-
ogy of the human colon in UC showing a thickened muscularis mucosae and additional al-
terations confined to the lamina propria without transmural involvement. (c) Pathology of 
the human colon in CD showing granulomas and transmural involvement. (d) Pathology 
of the bovine colon in a severe case of Johne’s disease showing lamina propria inflamma-
tion, granulomas, and a transmural process.
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lon cells, bacterial antigens (such as LPS), and foreign antigens (such as cow milk 
proteins) (165). These findings may be explained by the release of intestinal cell 
antigens. Immune complexes have also been invoked to explain extraintestinal 
manifestations of IBDs, such as arthritis (80). Cell-mediated immunological dam-
age is an attractive hypothesis because of the large number of macrophages or 
lymphocytes in the lesions. Associated abnormalities of cell-mediated immunity 
include anergy and decrease of peripheral T-cells (166). Moreover, dendritic cells 
(DC) may play an important role in this abnormal T-cell response because CD 
patients demonstrate elevated numbers of DC-SIGN+ (DC-specific intercellular 
adhesion molecule-grabbing nonintegrin) and CD83+ DC in colon tissues (158a). 
The involvement of the lectin-receptor DC-SIGN may also be relevant to the in-
fectious hypothesis (see below) because some pathogens, including M. tuberculo-
sis, bind DC-SIGN to subvert the normal antigen processing pathway (66a).
THE INFECTIOUS ETIOLOGY HYPOTHESIS:  
   THE CASE FOR M. paratuberculosis  
The chronic inflammatory nature of these diseases has prompted the search for a 
possible infectious etiology. Despite the numerous attempts to find known infec-
tious agents, none have been isolated. Microorganisms including Helicobacter py-
lori (131), MAP, Pseudomonas spp., and Yersinia spp. have been associated with the 
etiology of IBD (30, 89a). In addition, the Epstein-Barr virus and other cytophatic 
RNA intestinal viruses have been considered candidate etiologic agents (17, 89a). 
Several factors may be considered in the study of infectious causality of IBD. 
These factors may range from those described in the classical Koch’s postulates 
to establish etiology of infectious diseases to those including state-of-the-art mo-
lecular Koch’s postulates to identify virulence determinants (62, 95). In addition, 
some limitations of the Koch’ postulates must be considered when establishing 
disease causation, especially for cases in which the pathogen is difficult to isolate 
or culture. For these cases, new criteria of causality based on the application of 
nucleic acid sequence-based identification of microbial pathogens may be applied 
(65). In addition, Hill-Evans postulates based on strength, consistency, specificity, 
and temporality of agent-disease association may be helpful (61, 77). In this con-
text, IBD does not seem amenable to the application of the classical Koch’s postu-
lates. Although none of these factors are sufficient to prove or discard causality, 
their use may be helpful in narrowing a list of possible causative agents. The can-
didate agents can then be targets of further studies aimed to gather enough evi-
dence to sustain a case for causality. A recent application of Hill-Evans postulates 
to the MAP-CD etiological linkage did not reach a definitive conclusion, underly-
ing the difficulties involved in proving causality (17a).
The hypothesis that MAP could be the etiologic agent of CD was proposed 
years ago following the characterization of mycobactin-dependent mycobacteria 
isolated from resected gastrointestinal tissues of a few CD patients (32, 34). These 
isolates were pathogenic for mice and other laboratory animals, and most signif-
icantly they produced granulomatous disease of the distal intestine in an experi-
mentally infected baby goat (34). These findings were suggestive but fell short of 
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fulfilling the Koch’s postulates, since it is disease equivalence in animals and hu-
mans that is precisely in question. In addition, MAP isolates cannot always be re-
covered by culturing human specimens. An explanation for this difficulty came 
from further microscopic studies revealing the possible presence of spheroplas-
tic or cell wall–deficient (CWD) forms, also known as l-forms. Molecular meth-
ods were then used to identify these aberrant acid-fast negative forms as MAP 
(33, 167). This led to the MAP-CWD hypothesis for the etiology of CD: Low num-
bers of CWD forms of MAP, difficult to detect and isolate, are the causal agents of 
at least some cases of CD (30).
The existence of CWD forms in CD tissues could not be taken as factual be-
cause the evidence presented was preliminary and artifacts could not be ruled 
out. Protocols were later developed for the identification of CWD forms on the 
basis of in situ hybridization in tissue samples from animals and CD patients 
(84–86, 138a). In one case, 35 of 48 tissue samples of CD patients were positive 
for the presence of MAP within granulomas (138a). These methods are based on 
the use of low concentrations of proteinase K to disrupt tissue samples and de-
tect chemically generated CWD forms, and yielded positive results with tissue 
samples. Competent acid-fast bacilli are not detected by these methods. None-
theless, these procedures are based on the detection of DNA and do not defi-
nitely prove that viable CWD forms are detected in these tissues. Nonviable, 
partially or completely lysed cells may yield similar results. More recently, less 
disruptive methods such as confocal scanning laser microscopy (118) have been 
used in the search for CWD forms or competent bacilli in CD tissues. This tech-
nology has been applied to a few tissue samples, and more definitive conclu-
sions await a more comprehensive study. An elegant recent study generated 
CWD forms chemically by growing MAP in medium containing glycine fol-
lowed by lysozyme treatment (78). CWD forms remained viable and reverted 
to normal bacilli once the treatment was stopped. CWD forms did not display 
bands associated with cell wall glycolipids including lipoarabinomannan. Most 
importantly, sera from cattle with Johne’s disease reacted differently to CWD 
and competent bacilli, with CWD forms lacking the 21- to 30-kDa immunodom-
inant band observed normally. Nonetheless, it is not yet known whether these 
chemically generated forms are infectious or whether they are equivalent to 
CWD forms that might be generated in vivo.
Culturing from humans proceeded through the years and a significant num-
ber of MAP human isolates have been now cultured. More recently, the applica-
tion of short-term cultures using the mycobacterial growth indicator tube (MGIT) 
system yielded positive cultures in 6 of 7 resected tissue samples and in 4 of 20 
biopsy specimens obtained from CD patients (138). Positive cultures in resected 
tissue (closer to the active ulcer) were obtained in 10 to 12 weeks, while up to 
40 weeks were required for cultures from biopsies. Non-IBD controls yielded an 
overall 6% recovery of MAP-positive culture from sample specimens versus 37% 
recovery from CD patients. Moreover, there is one report that indicates positive 
MAP cultures from breast milk of lactating mothers with CD, a finding of signifi-
cant importance if confirmed by other laboratories (117).
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PCR technology for the detection of nucleic acid sequences has found MAP in 
intestinal tissues of CD patients, as reviewed elsewhere (76). A recent study used 
five methods for detection of MAP, adapted from diagnosis procedures for Joh-
ne’s disease, and found a higher level of MAP detection in CD and UC patients 
when compared with controls (43). However, the MAP etiology theory has re-
mained controversial because of conflicting results and differences in laboratory 
techniques among the various studies. In this context, recent observations (16) as 
well as previous studies have reported either positive or negative PCR test results 
for the identification of MAP from tissues of CD patients (72). Nonetheless, inves-
tigators who obtained positive tests have indicated that sample selection and pro-
cessing is of utmost importance to detect MAP DNA by PCR in material from hu-
man intestinal biopsies. When this methodology was used with primers uniquely 
specific to the IS900 element, MAP was detected in 92% of CD cases compared 
with 26% of non-IBD controls (23). Moreover, in this study, the use of MGIT led 
to a high degree of culture-positive IBD samples (14 of 33 CD cases versus 3 of 33 
non-IBD controls by PCR of MGIT cultures). Another approach used to detect the 
presence of viable MAP in CD patients was RT-PCR, which probes for the pres-
ence of RNA. In one study, eight CD, two UC, and two non-IBD controls samples 
of resected ileal mucosa were subjected to RT-PCR, yielding positive results for 
all the IBD samples (105). Nonetheless, finding MAP in CD patients is a proof of 
association rather than causality, and thus this theory has not yet been accepted. 
In addition, questions on the reproducibility of the various studies have loomed 
in the background.
Genetic Factors Underlying Resistance and Susceptibility 
IBD occurs more often in some racial groups and exhibits some familial cluster-
ing. This suggests that there may be a genetic predisposition to the development 
of the disease. In twin studies, 20% and 67% of monozygotic and 0% and 8% of 
dizygotic twins were concordant for UC and CD, respectively (164). Further in-
dication of genetic predisposition is the association of IBD with several genetic 
syndromes, including Turner’s syndrome (5). Hermansky-Pudlak syndrome, an 
autosomal recessive disorder, is associated with a granulomatous colitis (137). 
Crohn’s-like lesions may appear in the large and small intestine of patients with 
the autosomal recessive glycogen storage disease type 1b (136). Several immu-
nodeficiency disorders, including hereditary angioedema, hypoglammaglob-
ulinemia, and selective immunoglobulin A (IgA) deficiency are also associated 
with IBD (87).
Several chromosomal regions implicated in the predisposition to IBD have 
been identified. The chromosomes 16q, 12q, 1p, 1q, 3p, 3q, 5p, 6p, 7q, 14q, and 
19p may be specifically associated with CD (35). The locus on the chromosome 
16q 12 (IBD1 locus) has been associated with CD (83), and other loci such as the 
locus IBD2 on chromosome 12q contribute to IBD in general. These findings sug-
gest that the increase in the risk of intestinal inflammation is linked to specific 
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genes. The susceptibility gene located on chromosome 16 is the NOD2 (nucleo-
tide oligomerization domain), which codes for a protein involved in the initial re-
sponse of the immune system to bacterial infection (82, 119). This protein con-
tains two C-terminal caspase recruitment domains (CARDs) and is also called 
CARD15. In the case of NOD2/CARD15, self-binding results in activation of the 
protein, which contains a leucine-rich region that is critical for mediating the in-
teraction with bacterial polysaccharides (36). No correlation has been observed 
between these variants and UC. In subjects carrying one copy of any of these 
genes, the risk of developing the disease increases from 1.5- to 4-fold. Homozy-
gous individuals had an increased risk of 15- to 40-fold. NOD2 has been identi-
fied in Paneth cells of the intestinal tract, which suggests a role for NOD2 in the 
regulation of Paneth cell’s mediated response against intestinal bacteria. In addi-
tion, this finding may be a plausible explanation for the selective association of 
NOD2 mutations with ileal disease. The impaired capacity of patients with CD-
associated mutations to sense bacteria in the lumen may result in increased sus-
ceptibility to certain gut microbes (120). Because of the proposed role of NOD2 to 
directly bind bacterial LPS, and subsequently act as an activator of NF-κB, it has 
been proposed that this pathway would be characteristic of a Toll-like-receptor-
mediated recognition of LPS. The recent use of NOD2 knockout mice has dem-
onstrated that NOD2 does not play an essential role in macrophage response to 
bacterial products, but rather plays a role in regulating the systemic response to 
pathogens (129). A number of haplotypes, such as R702W, G908R, and L1007fs, 
have been linked to the disease. The presence of a susceptibility gene for CD on 
chromosome 5 has been recently established. When linkage disequilibrium map-
ping was used, a haplotype on chromosome 5, associated with a cytokine cluster, 
that confers susceptibility to CD was identified (135). The genotype relative risk 
for individuals who are heterozygous is twofold compared with approximately 
sixfold for homozygous individuals.
HLA alleles may also be involved in the genetic predisposition to IBD. For ex-
ample, an increased frequency of the DR5DQ1 haplotype or the DRB*0301 allele 
in CD has been described (102). In UC, the HLA DRB1*0103 allele has been asso-
ciated with extensive disease and extraintestinal manifestations. Other immuno-
regulatory genes that have been associated with IBD include the intercellular ad-
hesion molecule R241 allele in UC and CD (19) and the IL-1 receptor antagonist 
allele 2 in UC patients with pancolonic inflammation (175). In summary, all these 
findings provide evidence that the disease is a genetic disorder. However, other 
factors, such as an infection, may be needed to trigger the pathological process. 
Several characteristics of IBD have pointed at acquired factors that may be in-
volved in the etiology of the disease.
Serological Studies 
Another approach to study the possible role of MAP in the etiology of CD is to 
evaluate CD patients for the presence of antibodies reactive against MAP an-
tigens. Antibodies binding to a 38-kDa antigen were demonstrated in 57% of 
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CD patients, while antibodies to the 24- and 18-kDa bacterioferritin were sig-
nificantly elevated in 53% of the CD patients (54). However, reaction against 
those antibodies did not show any correlation with each other, and only 18% 
of patients were positive for all three antigens. Antibodies to the 45- to -48-kDa 
antigen were detected in approximately 67% of patients with CD, 10% of pa-
tients with UC, and 5% of patients with carcinoma of the colon. Health controls 
were negative (96). Another MAP antigen against which antibodies have been 
detected is an antigen of 36 kDa (p36). Patients with CD are usually positive for 
antip36 antibodies (approximately 89%), while a few UC cases react (approx-
imately 12%). Interestingly, 100% of patients immunized with BCG showed a 
positive reaction compared with 10% of normal controls (58). Several other stud-
ies have demonstrated that CD patients show specific reactivity to the p35 and 
p36 antigens (116). The predictive value and the sensitivity were 98%, which 
suggests a strong association between presence of MAP antigens and CD. How-
ever, both p35 and p36 are present in MAV, suggesting that a similar reaction 
will be obtained with the MAV p35 and p36 homologs. A proteomic approach 
may be used to compare the levels of expression of p35 and p36 in MAP and 
MAV, with the implication that a specific association of MAP with CD will be 
underscored by significantly higher levels of expression in MAP. Immune re-
sponse against the 14-kDa AhpC antigen in a large population of CD patients 
has also been demonstrated (125). In this case, AhpC expresses constitutively 
and at high levels in MAP (124).
Other mycobacterial antigens considered are the heat shock proteins. Because 
of the degree of conservation between bacterial and host 65-kDa proteins, it has 
been proposed that bacterial antigens might induce antibodies that cross-react 
with host tissues. As with PCR studies, both positive and negative cross-reactions 
with serum from CD patients have been reported (15, 152). Likewise, additional 
studies with antibodies against the 18-kDa bacterioferritin antigen yielded no dif-
ferent results between CD patients and control individuals (168). Negative cross-
reactive results against different antigens have also been reported (150).
Other immunological tests useful for the diagnosis of IBD are based on the 
presence of abnormal IgG and IgA antibodies in IBD patients owing to the devel-
opment of food allergies (126). Most notably, serum samples from IBD patients 
develop antineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces 
cerevisiae mannan antibodies (ASCA) (158). Prevalence of ASCA and ANCA an-
tibodies has been found in the range of 50 to 60% in both CD and UC patients 
(132). A recent report combining ANCA and ASCA markers with the MAP anti-
gens p35 and p36 yielded a test with 95% sensitivity for the detection of CD (143).
Intestinal bacteria have been increasingly implicated as an environmental fac-
tor in IBD owing to their mucosal localization and antigenic components. Co-
lonic bacteria are antigenic targets for disease-associated T- and B-cell immune 
responses in the C3H/HeJBir mouse (18). In this context, Cohavy et al. (41) de-
scribed the identification of a mycobacterial protein, HupB, for which the pres-
ence of specific IgA was associated with CD. It is of relevance that HupB shares 
cross-reactive epitopes with the mammalian histone H1, the antigen associated 
with ANCA, a characteristic immune response in IBD. Moreover, MAP and MAV 
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express more HupB than other mycobacterial species. This observation led to the 
speculation that HupB-like proteins produced by MAP and other colonic bacteria 
may trigger the onset of CD. In this way, a MAP-shared antigen (HupB), rather 
than live bacilli, would be involved in the etiology of CD. It is tempting to specu-
late that CWD forms of MAP may have a depot effect on the release of HupB and 
thus contribute to the maintenance of the inflammatory process, at least in some 
cases of CD.
Chemotherapy 
Another approach to identify disease causation is the use of chemotherapeutic 
agents to eliminate the infectious agents. The caveat of this approach is that an-
timicrobial agents act against a broad range of bacterial pathogens and may also 
have a generalized nonspecific effect on the host. In this context, various stud-
ies have been or are being conducted to examine the effect of regimens that have 
been proved active against infections caused by MAV. In one of these trials, CD 
patients were randomized to receive either clarithromycin (500 mg twice daily) 
and ethambutol (15 mg/kg/day) or identical appearance placebos for 3 months 
in addition to their regular therapy. After 3 months of treatment, no signs of im-
provement were detected in patients with CD (67). Another study used clarithro-
mycin (250 mg twice daily) in combination with rifabutin (150 mg twice daily) in 
an open clinical trial with 29 patients. In this case, approximately 58% of patients 
reported significant improvement following the period of therapy. Only five pa-
tients were nonresponders (142). Additional large-scale chemotherapeutic trials 
are in progress.
Animal Models 
One of the major problems regarding the establishment of the relationship be-
tween MAP and CD is the absence of an animal model that can reproduce the hu-
man disease. Animal models have been created to investigate aspects of Johne’s 
disease. Mouse models have been employed to study the MAP response to antibi-
otics. Some models using immunosuppressed mice, such as the nude mice, have 
demonstrated multiplication of the bacterium in the intestinal mucosa (71). In ad-
dition, formation of the granulomas is in certain cases similar to those observed 
in either Johne’s disease or CD. The SCID-beige mice have also been used with 
success. Lesions usually develop, compromising the whole intestinal mucosa, fol-
lowing infection with a relatively small number of organisms (113). Another po-
tential model is the Dark Agouti rats because they carry alleles enhancing the sus-
ceptibility to autoimmune and inflammatory diseases, including IBD, in mice and 
humans (91). It would be of interest to determine whether MAP infection of these 
animals leads to IBD disease that more closely resembles the human condition.
A newborn rabbit model with oral inoculation of bacteria has also been also 
developed. Nine of 21 rabbits presented granulomatous enteritis, while 14 had di-
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arrhea (106). Therefore, although the models can be used to study specific aspects 
of CD, they are far from ideal to examine if the etiology of CD is due to MAP in-
fection. While infection of sheep is still feasible for the study of Johne’s disease, it 
appears that the goat is the animal in which infection with MAP resembles most 
lesions of CD (94). Sogawa et al. (145) developed a murine model of granuloma-
tous colitis by intramural injection of mycobacterial cord factor into the intestine. 
A single dose injected in the form of liposome triggered the appearance of gran-
uloma in the infection site (145). The granuloma was composed of macrophages 
and CD4 and CD8 lymphocytes. Mucosal erosion or ulceration was not induced. 
Nonhuman primates have not been investigated. Recent reports have demon-
strated that monkeys are excellent models for both tuberculosis and leprosy, as 
they develop disease that is similar to the human case (27). Although primates 
are expensive, and their use is under tight regulatory rules, it would be interest-
ing to evaluate if human and bovine strains of MAP would cause intestinal infec-
tion that resembles CD. Because the interval between ingestion and development 
of disease is unknown, this experimental approach is labor intensive, time-con-
suming, and not without difficulties.
Concluding Remarks
We have presented an overview of the overt or potential pathogenicity of MAP in 
both human and veterinary medicine. These observations can be summarized as 
follows. (a) Application of the Koch’s postulates clearly defined MAP as the eti-
ologic agent of Johne’s disease in ruminants, a disease that resembles some as-
pects of CD in humans. (b) Given the close genetic relationship between MAP 
and MAV and their pathogenicity for a wide range of animal hosts, MAP may 
be at least an opportunistic pathogen of humans. (c) Tropism of MAP for the in-
testinal mucosa in ruminants suggests a preferential tropism for the gastrointes-
tinal cavity in humans. (d) As methods for detection and isolation of MAP in hu-
man tissues and serology have improved, the association between CD and MAP 
colonization has become stronger. This is not the case for UC. (e) There are no evi-
dent sources of MAP infection for humans, though environmental or wildlife res-
ervoirs have been suggested. Direct transmission from adulterated bovine milk 
consumption is another less likely possibility.
On the basis of these considerations, the relationship of MAP to CD may be 
causal, implicating MAP as the etiologic agent of all or a subset of CD cases. Al-
ternatively, the characteristic inflammatory damage of the intestinal mucosa and 
pattern of cytokine expression in CD patients may create conditions favorable for 
the colonization of MAP as an opportunistic pathogen. The latter situation may 
even lead to the maintenance or recrudescence of the inflammatory condition 
characteristic of CD patients. An etiologic role of MAP in CD would suggest a 
chemotherapeutic regimen with antimycobacterial agents specific to MAP as the 
best course of action for the treatment of CD. In contrast, an opportunistic role 
of MAP would advocate the use of rifabutin or other prophylactic treatment in 
a fashion similar to that recommended for MAV in AIDS patients. However, if 
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CD is mediated by an altered immunological reaction to an antigen, including a 
MAP protein, antimicrobial chemotherapy may be counterproductive. These is-
sues underscore the need to develop suitable animal models of CD to test these 
divergent hypotheses prior to undertaking extensive clinical trails with antimy-
cobacterial agents. These models may also allow the application of Koch’s pos-
tulates to CD. Nonetheless, the answer to the role of MAP in CD etiology may 
come from the consistent results of improved methods of isolation and detection 
of MAP bacilli or MAP-elicited immune responses in the host, results of animal 
models, and, eventually, the outcomes of well-designed clinical trials with che-
motherapeutic agents. Alternatively, more rapid progress may come from a find-
ing that provides a unified explanation for the different set of phenomena associ-
ated with CD. In this context, the analysis of the HupB antigen and other related 
histone-like proteins may be an important research avenue to pursue that could 
explain the role of MAP and colonic bacteria in IBD.
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